Telomir Pharmaceuticals, Inc. (TELO) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Telomir Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Telomir-1, a novel oral small molecule designed to regulate metal ions (iron, copper, zinc) to combat oxidative stress and preserve telomere integrity. The company targets age-related conditions such as Progeria, Wilson's disease, and Age-related Macular Degeneration (AMD), as well as viral infections. The company has generated no revenue to date and relies on external financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(5,069,890) | $(7,249,718) | N/A |
| Operating Expenses | $5,069,910 | $7,257,692 | N/A |
| General & Administrative (G&A) | $5,027,071 | $6,877,857 | N/A |
| Research & Development (R&D) | $42,839 | $379,835 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $754,323 |
| Total Assets | N/A | N/A | $829,611 |
| Total Liabilities | N/A | N/A | $348,388 |
| Stockholders' Equity | N/A | N/A | $481,223 |
| Weighted Avg. Shares Outstanding | 30,010,165 | 30,265,285 | 30,514,304 (Issued) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the three months ended June 30, 2025, increased to $5.1 million from $1.4 million in the same period in 2024. The six-month loss decreased slightly to $7.2 million from $7.7 million in 2024.
- Expense Surge: General and Administrative expenses surged to $5.0 million (Q3) and $6.9 million (YTD) compared to $0.9 million and $1.6 million in 2024, respectively. This increase is primarily driven by $4.6 million in stock-based compensation for the quarter and $6.0 million for the six months.
- R&D Decrease: R&D expenses decreased significantly to $42,839 (Q3) and $379,835 (YTD) from $594,801 and $1.4 million in 2024. Management attributes the 2024 higher costs to specific study credits and manufacturing activities not present in 2025.
- Cash Position: Cash balances declined from $1.27 million at December 31, 2024, to $0.75 million at June 30, 2025, reflecting a net cash outflow from operations of $1.56 million for the six-month period.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. Management expects cash to be sufficient only through the third quarter of 2026, contingent on raising additional capital.
- Financing Activities: The company raised approximately $1.05 million in the quarter via stock sales. Subsequent events (July 2025) include an additional $2.9 million raised via an At-The-Market (ATM) offering and the completion of a $3 million investment from The Bayshore Trust.
- Operational Highlights: The company announced new preclinical data for Telomir-1 regarding Werner Syndrome, Wilson's disease, and prostate cancer, as well as the identification of a new candidate, Telomir-Ag2.
- Risks: Key risks include the inability to secure additional funding, failure to obtain regulatory approval, and the high cost of clinical trials. The company has no revenue and expects losses to continue.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $0.75 million cash balance against the projected burn rate and the timeline for the next financing round.
- Stock-Based Compensation: Review the $6.0 million in non-cash stock compensation expenses and the dilution impact of recent grants (including 2 million options to the CEO).
- Related Party Transactions: Confirm the terms of the $5 million unsecured line of credit with the Starwood Trust and the $3 million investment from The Bayshore Trust.
- Intellectual Property: Assess the status of the exclusive license agreement with MIRALOGX, LLC, including the 8% royalty obligation on future net sales.
- Subsequent Events: Confirm the closing of the July 2025 ATM offering and the full receipt of funds from The Bayshore Trust.